Advanced search
Publication Cover
SAR and QSAR in Environmental Research Volume 28, 2017 - Issue 10: Special Issue: 9th International Symposium on Computational Methods in Toxicology and Pharmacology Integrating Internet Resources (CMTPI-2017) - Part 1. Guest Editors: A.K. Saxena and M. Saxena
Submit an article Journal homepage
448
Views
20
CrossRef citations to date
0
Altmetric
Special Issue: 9th International Symposium on Computational Methods in Toxicology and Pharmacology Integrating Internet Resources (CMTPI-2017) - Part 1. Guest Editors: A.K. Saxena and M. Saxena

In silico prediction of multiple-category classification model for cytochrome P450 inhibitors and non-inhibitors using machine-learning methodFootnote$

J. H. LeeNational Leading Research Laboratory (NLRL) of Molecular Modeling & Drug Design, College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea
,
S. BasithNational Leading Research Laboratory (NLRL) of Molecular Modeling & Drug Design, College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea
,
M. CuiNational Leading Research Laboratory (NLRL) of Molecular Modeling & Drug Design, College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea
,
B. KimNational Leading Research Laboratory (NLRL) of Molecular Modeling & Drug Design, College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea
&
S. ChoiNational Leading Research Laboratory (NLRL) of Molecular Modeling & Drug Design, College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of KoreaCorrespondence[email protected]
Pages 863-874 | Received 27 Oct 2017, Accepted 29 Oct 2017, Published online: 29 Nov 2017

References

  • A.E. Klon, Machine learning algorithms for the prediction of hERG and CYP450 binding in drug development, Expert Opin. Drug Metab. Toxicol. 6 (2010), pp. 821–833.
  • M. Lapins, A. Worachartcheewan, O. Spjuth, V. Georgiev, V. Prachayasittikul, C. Nantasenamat, and J.E. Wikberg, A unified proteochemometric model for prediction of inhibition of cytochrome p450 isoforms, PLoS One 8 (2013), p. e66566.
  • R. Arimoto, Computational models for predicting interactions with cytochrome p450 enzyme, Curr. Top. Med. Chem. 6 (2006), pp. 1609–1618.
  • K. Roy and P.P. Roy, QSAR of cytochrome inhibitors, Expert Opin. Drug Metab. Toxicol. 5 (2009), pp. 1245–1266.
  • R.J. Vaz and R. Klabunde (ed.), Antitargets, Wiliey-VCH Verlag GmbH, Weinham, 2008.
  • R. Arimoto, Computational models for predicting interactions with cytochrome p450 enzyme, Curr. Topics Med. Chem. 6 (2006), pp. 1609–1618.
  • Y. Wang, J. Xiao, T.O. Suzek, J. Zhang, J. Wang, Z. Zhou, L. Han, K. Karapetyan, S. Dracheva, B.A. Shoemaker, E. Bolton, A. Gindulyte, and S.H. Bryant, PubChem’s bioAssay database, Nucleic Acids Res. 40 (2012), pp. D400–D412.
  • P. Vasanthanathan, O. Taboureau, C. Oostenbrink, N.P. Vermeulen, L. Olsen, and F.S. Jorgensen, Classification of cytochrome P450 1A2 inhibitors and noninhibitors by machine learning techniques, Drug Metab. Dispos. 37 (2009), pp. 658–664.
  • S. Novotarskyi, I. Sushko, R. Korner, A.K. Pandey, and I.V. Tetko, A comparison of different QSAR approaches to modeling CYP450 1A2 inhibition, J. Chem. Inf. Model. 51 (2011), pp. 1271–1280.
  • F. Cheng, Y. Yu, J. Shen, L. Yang, W. Li, G. Liu, P.W. Lee, and Y. Tang, Classification of cytochrome P450 inhibitors and noninhibitors using combined classifiers, J. Chem. Inf. Model. 51 (2011), pp. 996–1011.
  • H. Sun, H. Veith, M. Xia, C.P. Austin, and R. Huang, Predictive models for cytochrome p450 isozymes based on quantitative high throughput screening data, J. Chem. Inf. Model. 51 (2011), pp. 2474–2481.
  • M. Rostkowski, O. Spjuth, and P. Rydberg, WhichCyp: Prediction of cytochromes P450 inhibition, Bioinformatics 29 (2013), pp. 2051–2052.
  • B. Manavalan and J. Lee, SVMQA: Support-vector-machine-based protein single-model quality assessment, Bioinformatics 33 (2017), pp. 2496–2503.
  • B. Manavalan and J. Lee, Random forest-based protein model quality assessment (RFMQA) using structural features and potential energy terms, PLoS One 9 (2014), p. e106542.
  • B. Manavalan, S. Basith, T.H. Shin, S. Choi, M.O. Kim, and G. Lee, MLACP: Machine-learning-based prediction of anticancer peptides, Oncotarget 8 (2017), pp. 77121–77136.
  • J.H. Lee, S. Lee, and S. Choi, In silico classification of adenosine receptor antagonists using Laplacian-modified naive Bayesian, support vector machine, and recursive partitioning, J. Mol. Graph. Model. 28 (2010), pp. 883–890.
  • H. Veith, N. Southall, R. Huang, T. James, D. Fayne, N. Artemenko, M. Shen, J. Inglese, C.P. Austin, D.G. Lloyd, and D.S. Auld, Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries, Nat. Biotechnol. 27 (2009), pp. 1050–1055.
  • G. Cruciani, M. Pastor, and W. Guba, VolSurf: A new tool for the pharmacokinetic optimization of lead compounds, Eur. J. Pharm. Sci. 11 (2000), pp. S29–S39.
  • X.Y. Xia, E.G. Maliski, P. Gallant, and D. Rogers, Classification of kinase inhibitors using a Bayesian model, J. Med. Chem. 47 (2004), pp. 4463–4470.
  • P. Baldi, S. Brunak, Y. Chauvin, C.A.F. Andersen, and H. Nielsen, Assessing the accuracy of prediction algorithms for classification: An overview, Bioinformatics 16 (2000), pp. 412–424.
  • K.K. Chohan, S.W. Paine, J. Mistry, P. Barton, and A.M. Davis, A rapid computational filter for cytochrome P450 1A2 inhibition potential of compound libraries, J. Med. Chem. 48 (2005), pp. 5154–5161.
  • P. Vasanthanathan, O. Taboureau, C. Oostenbrink, N.P.E. Vermeulen, L. Olsen, and F.S. Jorgensen, Classification of cytochrome P450 1A2 inhibitors and noninhibitors by machine learning techniques, Drug Metab. Disp. 37 (2009), pp. 658–664.
  • S. Ekins, M.J. De Groot, and J.P. Jones, Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites, Drug Metab. Disp. 29 (2001), pp. 936–944.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.